# OnCo record checkmate-238 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/checkmate-238/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "checkmate-238", "NCT02388906" ;
  schema:name "CheckMate 238"@en ;
  schema:description "CheckMate 238 showed that a year of nivolumab after melanoma surgery prevents more relapses than the older drug ipilimumab, with far fewer serious side effects, and it made PD-1 blockade the standard adjuvant treatment."@en ;
  schema:url <https://onco.cc/trials/checkmate-238/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02388906>, <https://www.nejm.org/doi/full/10.1056/NEJMoa1709030>, <https://doi.org/10.1016/S1470-2045(20)30494-0> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/stage-iii-melanoma/>, <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/efs/> ;
  onco:people <https://onco.cc/people/jeffrey-weber/>, <https://onco.cc/people/james-larkin/>, <https://onco.cc/people/paolo-ascierto/> .